SALT LAKE CITY, March 09, 2017 -- LifeVantage Corporation (Nasdaq:LFVN), announced today the appointment of Charles J. Wach as Chief Operating Officer, effective March 13, 2017.
“We are pleased to have Charles ‘Chuck’ Wach join the company as COO,” said LifeVantage President and Chief Executive Officer, Darren Jensen. “He is an accomplished leader with operations experience in the nutritional supplement, direct selling, online retail, and global food and beverage industries. His proven skills will help us to enhance our operations and deliver shareholder value. Additionally, Chuck’s supply-chain expertise and relationships with suppliers and manufacturers across salient product categories will expand our sourcing and manufacturing resources, broadening our supply chain and increasing efficiencies.”
“I am genuinely honored and excited to join the talented leaders at LifeVantage,” said Wach. “I look forward to safeguarding and strategically expanding the company’s well-curated, efficacious product portfolio. It is a true privilege to join such an incredible company, and I’m confident that my team and I will deliver new value to our distributors, shareholders and LifeVantage itself.”
Mr. Wach brings more than 30 years of operations and leadership experience, having served in multiple senior operational roles with relevant industry experience. Most recently, Mr. Wach served as Vice President of Operations and Supply Chain Executive for Bodybuilding.com, Inc., a global internet specialty retailer, from 2013 to 2017. Mr. Wach also served as Director of Global Supply Chain, Materials Management for Nature’s Sunshine Products, Inc. He has filled several operational roles for Nestle-Perrier Group of America Inc., H.J. Heinz Co., and Frito Lay, Inc. Mr. Wach received his Master of Business Administration degree from Utah State University and his Bachelor of Science degree in Finance from Brigham Young University.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq:LFVN), is a science-based direct selling company dedicated to visionary science that looks to transform health, wellness and anti-aging internally and externally at the cellular level. The company is the maker of Protandim ® Nrf2 and NRF1 Synergizers, its line of scientifically-validated dietary supplements, the TrueScience® Anti-Aging Skin Care Regimen, Canine Health®, the AXIO® energy product line and the PhysIQ™ Smart Weight Management System. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah. www.lifevantage.com
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe", "hopes", "intends", "estimates", "expects", "projects", "plans", "anticipates", "look forward to", "goal", "may be", "should", and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding our leadership transition, future growth, and shareholder value. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
Investor Relations Contacts: Cindy England Director of Investor Relations (801) 432-9036 [email protected] -or- Scott Van Winkle Managing Director, ICR (617) 956-6736 [email protected]


Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 



